Lumida
/INFU
⌘K
InfuSystem Holdings Inc

InfuSystem Holdings Inc

INFU
$12.15USD+0.25%+0.03 today

MARKET CAP

242.0M

P/E (TTM)

32.8x

FWD P/E

DAY RANGE

$12 – $12

52W RANGE

$7
$13

AI Summary

Stalk
StalkMedium

Following INFU’s robust early August momentum breakout, price is tightly consolidating near rising 9- and 20-EMA support with EMAs in bullish alignment. Medium-term bullish structure remains intact while short-term timing is neutral, warranting patience and stalking for a pullback entry into the 9/20 EMA zone.

  • Q2 revenue $36.9M, up 2.6% YoY (~7.5% ex restructuring) driven by oncology volume
  • Wound care revenue jumped 154% YoY to $2.1M on compression devices
  • GE contract restructuring trimmed Q2 revenue by $1.6M, highlighting partnership risk
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$102.4M$109.9M$125.8M$134.9M$143.4M
YoY %+5.1%+7.4%+14.4%+7.2%+6.4%
P / Sales3.7x1.7x1.8x1.4x1.3x
EV / Sales4.1x2.2x2.2x1.7x1.6x
Gross Profit, Adj.$58.5M$60.6M$63.1M$70.4M$80.3M
YoY %-0.4%+3.5%+4.2%+11.6%+14.1%
Margin %57.2%55.1%50.2%52.2%56.0%
EV / Gross Profit7.3x3.9x4.3x3.3x2.9x
EBITDA, Adj.$17.4M$15.0M$16.6M$19.4M$25.2M
YoY %-23.7%-13.9%+10.5%+16.8%+30.0%
Margin %17.0%13.7%13.2%14.4%17.6%
EV / EBITDA24.3x15.9x16.3x11.8x9.1x
EBIT$2.8M$1.7M$4.1M$6.9M$11.9M
YoY %-68.1%-41.3%+147.2%+68.6%+73.0%
Margin %2.8%1.5%3.2%5.1%8.3%
EV / EBIT150.6x144.3x66.3x33.2x19.2x
Net Income$1.4M$18,000$872,000$2.3M$6.6M
YoY %-91.8%-98.7%+4744.4%+168.9%+182.6%
Net Margin1.4%0.0%0.7%1.7%4.6%
EPS (GAAP)$0.06$0.04$0.11$0.31
YoY %-92.5%+175.0%+181.8%